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Fructose consumption has steadily increased in West-
ern countries, with adolescents consuming up to 70 g of 
fructose per day [1]. Apples, pears or grapes contain ~8 g 
fructose per 100 g; however, most fructose intake is de-
rived from processed sugars in many contemporary foods 
and sweetened beverages. Fructose is 1.5–2.5 times sweet-
er than glucose; however, it fails to activate normal satiety 
signals, increasing caloric intake and weight gain. Spe-
cific metabolic properties of fructose further contribute 
to metabolic syndrome, and fructose consumption has 
now become a public health concern [2]. 
Digestive discomfort after fructose intake also im-
pacts the health. Food intolerance disorders affect ap-
proximately 20% of the general population [3] and 70% 
of individuals with functional gastrointestinal disorders 
(FGID) [4]. Fructose is frequently blamed as a cause for 
symptoms such as diarrhea, pain, and bloating. 
Fructose absorption is mediated by the passive glucose 
transporter GLUT5 and the active glucose transporter 
GLUT2; however, small intestinal fructose resorption ca-
pacity is limited [5]. Non-resorbed fructose will be me-
tabolized by the colonic microbiota, leading to the pro-
duction of CO2, H2, CH4, short-chain fatty acid, and pos-
sibly intestinal symptoms. The fructose H2 breath test 
(FHBT) aims to identify individuals with (i) fructose 
“malabsorption,” assessed by high H2 values in expiratory 
air and (ii) symptoms after oral fructose challenge (“in-
tolerance”). To date, the clinical impact of FHBT remains 
unclear. 
A paper in this issue of Digestion addresses this ques-
tion (Helwig et al. [6], Digestion, 2018). The authors 
analyze 562 consecutive 50 g FHBT. As expected for a 
high-dose fructose challenge [7], FHBT showed fruc-
tose malabsorption in a large proportion of individuals 
(66.5%). H2-levels correlated with symptoms during the 
test, confirming that breakdown products of poorly ab-
sorbed fermentable oligo-, di-, and mono-saccharides 
and polyols (FODMAPs) contribute to the occurrence 
and severity of symptoms [8]. 
The most interesting part of this work was the impact 
of professional dietary advice to 246 patients with a posi-
tive FHBT with symptoms. Patients completed a 10-day 
“open-label” fructose-free diet. Almost half (47%) the pa-
tients responded completely and 45% partially to this in-
tervention. However, neither the H2 response nor the 
symptoms during testing significantly predicted this di-
etary response. 
This is, to our knowledge, the largest study addressing 
the clinical utility of FHBT [9, 10]. The negative outcome 
cautions against non-critical interpretation of FHBT. In-
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deed, based on this data, the clinical utility FHBT seems 
to be so limited that this test might have no role in clinical 
practice. 
This study has several limitations: (i) Neither patients 
nor therapists were blinded to FHBT results, and strong 
placebo effects regarding dietary interventions were 
known in FGID patients. (ii) Lack of a control group (or 
control diet). (iii) Fructose exclusion might also exclude 
other compounds responsible for food intolerance. (iv) 
Fructose-free diet was not offered to patients with nega-
tive FHBT. Therefore, the negative predictive value of 
FHBT remains unknown. (v) No long-term outcome data 
(> 10 days) are provided.
One also wonders whether results of this trial would 
have been different with a lower fructose dosage. Fifty 
grams fructose (corresponding to 800 mL of a sweet-
ened beverage or 600 g apples) might not cause symp-
toms when taken with normal food since uptake of fruc-
tose is facilitated in the presence of glucose and with 
food. Conversely, high amounts of pure fructose might 
exceed fructose absorption capacity in most humans 
and a smaller dose would likely reduce false positive re-
sults. 
The negative results of the Helwig study are in line 
with data demonstrating a similar expression of GLUT2, 
GLUT5 mRNA and protein in small bowel biopsies in 11 
individuals with intolerance symptoms and positive 
FHBT and 15 control individuals without fructose intol-
erance and normal FHBT [11]. Another study demon-
strated reduced GLUT5 expression in inflammation [12], 
reminiscent to induction of lactose malabsorption by 
chronic viral infections [13]. Further, fructose treatment 
increased GLUT5 expression in the murine gut 5 times 
[5], suggesting that fructose exposure before FHBT might 
strongly influence the results. 
For most FGID, the burden of symptoms is deter-
mined not only by altered motility or digestion, but 
also by visceral sensitivity to gastrointestinal events. For 
instance, 20 g lactose hydrogen breath test is three 
times  more likely to produce symptoms in patients 
with  irritable bowel syndrome (IBS) than in healthy 
controls [14]. Moreover, a recent study showed that co-
lon hypersensitivity to gas distension, more than gas 
production itself, produces symptoms in IBS patients 
[15]. 
Further, considering the complexity of our nutrition, 
fructose will rarely be the only offender. Rather than fo-
cusing on individual carbohydrates, the FODMAP hy-
pothesis suggests that a wide range of poorly absorbed 
carbohydrates can cause functional gastrointestinal 
symptoms [8]. The low-FODMAP diet will simultane-
ously reduce all offenders, relieving symptoms in approx-
imately 70% of IBS patients [8]. 
Looking ahead, the ideal clinical investigation would 
predict the response to a well-validated dietary interven-
tion. Symptoms after a lactulose challenge (an indigest-
ible FODMAP producing an H2-response in most pa-
tients) [16] might confirm FODMAPs as a trigger for 
symptoms of a given patient. Blinded testing of various 
FODMAPs could also help guiding a rational exclusion 
of compounds. The goal of testing should be to identify 
patients benefiting from a diet and compounds to be ex-
cluded.
Finally, the report by Helwig et al. [6] showed that diet 
relieved symptoms at least partially in 92% of patients. 
Therefore, for patients with FGID, showing interest in 
patient’s symptoms, investigating the respective patho-
genesis as well as providing a clear disease concept and a 
therapeutic plan can benefit many patients. 
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